Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorLegacy Health System
About this trial
The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery.
The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery
Eligibility criteria
Qualifiers
Adults over 18 years of age with newly diagnosed, previously untreated, HR+, HER2+ breast cancer (positive per local guidelines)
Endocrine therapy for the current breast cancer may be started within 28 days prior to trial enrollment and must be initiated prior to C2 of chemotherapy/HER2 directed therapy
Choice of endocrine therapy will be determined by the treating and/or enrolling physician
Anatomic Stage IIA - IIIC breast cancer planning a minimum of 4 cycles of TCHP
Disqualifiers
Children under 18 years of age, pregnant women, prisoners, and decisionally impaired adults.
Patients with non-breast cancer within prior 2 years
Patients with breast cancer within prior 5 years
Patients with recurrent breast cancer
Trial design
Treatments tested in this trial
- Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
4Legacy Mount Hood Medical Center97030, GreshamOregon, United States
Legacy Good Samaritan Medical Center97210, PortlandOregon, United States
Legacy Meridian Park Medical Center97062, TualatinOregon, United States
Legacy Salmon Creek Medical Center98686, VancouverWashington, United States
Sponsors and collaborators
Legacy Health System
Lead sponsor
Source ClinicalTrials.gov